MYB and prostate carcinoma: The overexpression of MYB is widely observed in cancer cells and it’s oncogenic activity has been confirmed in leukemia (Pattabiraman and Gonda, 2013), breast cancer (Quintana et al, 2011), prostate cancer (Acharya et al, 2023), and other cancers (Ramsay and Gonda, 2008).